Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 8/20 | 0.37 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 5/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24112408 | 0.97 | TTK (0.36) | TTKPTK6SYKMAP3K7CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL30385325 | 0.96 | TTK (0.36) | TTKPTK6SYKMAP3K7CYP3A4 | |
| SCHEMBL25450694 | 0.93 | PTK6 (0.40) | TTKPTK6MAPKAPK5AURKAEGFR | |
| SCHEMBL22123694 | 0.92 | TTK (0.41) | TTKPTK6MAP3K7CYP3A4CYP2C9 | |
| SCHEMBL30172065 | 0.92 | TTK (0.41) | TTKPTK6MAP3K7CYP3A4CYP2C9 | |
| SCHEMBL25173551 | 0.88 | GPR119 (0.38) | TTKPTK6 | |
| SCHEMBL25450726 | 0.85 | PTK6 (0.38) | TTKPTK6MAPKAPK5 | |
| SCHEMBL22124340 | 0.84 | CDK2 (0.44) | TTKPTK6SYKCDK2MAPKAPK5 | |
| SCHEMBL22123440 | 0.83 | PTK6 (0.43) | TTKPTK6MAPKAPK5AURKA | |
| SCHEMBL30171744 | 0.83 | PTK6 (0.43) | TTKPTK6MAPKAPK5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | TTK 4336/4885PTK6 925/4885SYK 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.